Arjan Roskam Says Edibles Will Replace Medicine in 25 Years. Is He Right?

The claim

Arjan Roskam, the Dutch cannabis entrepreneur behind Green House Seed Company and the Strain Hunters documentary series, has been making a specific prediction in recent interviews and appearances: within 25 years, cannabis edibles will be a mainstream medical product. Properly dosed, delivering the therapeutic benefits of THC and other cannabinoids, with none of the downsides of smoking. Edibles as medicine, not as recreation.

Who is Arjan Roskam

Roskam is one of the most recognized figures in cannabis history. He founded the first Green House coffeeshop in Amsterdam in 1992 and built Green House Seed Company into one of the most awarded cannabis genetics brands in the world, with over 40 Cannabis Cup victories. His Strain Hunters series documented expeditions to find and preserve rare cannabis landraces around the world. He's controversial: critics accuse him of taking credit for genetics he didn't develop and of commercializing work done by others. But his influence on the global cannabis industry is hard to dispute, and his recent focus on edibles and medical applications suggests he sees the next chapter of cannabis in food, not flower.

The case for his thesis

The edibles market is growing at 16 to 22% annually. Precision dosing technology is making edibles as reliable as pharmaceutical pills. Research on cannabinoids for chronic pain, inflammation, sleep, and nausea continues to accumulate positive findings. The smoke-free trend is permanent: nearly half of cannabis consumers already use edibles. And the pharmaceutical industry is watching closely. Epidiolex (a CBD-based drug for epilepsy) proved that cannabis-derived compounds can pass FDA scrutiny. More pharmaceutical-grade cannabinoid products are in development.

The case against

Twenty-five years is a long time, but the regulatory barriers are enormous. Cannabis remains Schedule I federally in the US, and most countries still classify it as a controlled substance. The FDA has approved exactly one cannabis-derived drug in its history. Clinical trials for cannabinoid medicines are expensive, slow, and complicated by the legal status of the plant. And the edibles industry has a credibility problem: too many brands make health claims that go far beyond what the science supports, which undermines the legitimacy that medical acceptance requires.

Our take

Roskam's direction is right. Edibles are moving toward the medical mainstream, driven by consumer demand, research, and the inherent advantages of oral dosing (precision, duration, no lung damage). Whether it takes 25 years or 40 depends on regulatory willingness and the quality of clinical evidence that accumulates. The brands that treat edibles as a medical delivery format (1906, Care By Design) are ahead of this curve. The brands that treat them purely as recreational candy will still exist but won't be the ones driving the medical conversation. Either way, the trajectory Roskam describes is already underway. The question is speed, not direction.